Lexaria Bioscience Corp. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH $(DHT)$ study arms compared to the Rybelsus® control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus®. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120399) on December 23, 2025, and is solely responsible for the information contained therein.